Approximately 30,000 males have hemophilia in the U.S., according to estimates from a recent study, which also found that…
Articles by Marisa Wexler, MS
Three hemophilia B patients said they were able to lead a relatively normal life, including being more active and…
Data from a completed Phase 2b trial indicate that dalcinonacog alfa (DalcA) is an effective and safe therapy to prevent bleeding…
The U.S. Food and Drug Administration (FDA) has accepted — under priority review — a marketing application for…
When administered at a high dose, a gene therapy for hemophilia B known as FLT180a seems able to restore the…
Esperoct (turoctocog alfa pegol) is now available in the U.S. to treat and control bleeding in adults and children…
A modified version of the coagulation protein factor X was able to significantly reduce bleeding in a mouse model of…
Ease of use, fear of the unknown, and healthcare providers’ advice are all major factors that play a role in…
A single injection of uniQure‘s gene therapy AMT-061 (etranacogene dezaparvovec) is well-tolerated, effectively increases the levels of clotting…
The Fitbit wristband can help with the continuous monitoring of physical activity in people with hemophilia, but other…